Results of a worldwide survey on the currently used histopathological diagnostic criteria for invasive lobular breast cancer.

Autor: De Schepper M; Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium., Vincent-Salomon A; Diagnostic and Theranostic Medicine Division, Institut Curie, PSL Research University, Paris, France., Christgen M; Institute of Pathology, Hannover Medical School, Hannover, Germany., Van Baelen K; Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium., Richard F; Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium., Tsuda H; Department of Basic Pathology, National Defense Medical College Hospital, Tokorozawa, Saitama, Japan., Kurozumi S; Department of Breast Surgery, International University of Health and Welfare, Narita, Chiba, Japan., Brito MJ; Breast Unit, Champalimaud Clinical Center, Champalimaud Foundation, Lisbon, Portugal., Cserni G; Department of Pathology, Bács-Kiskun County Teaching Hospital, Kecskemét, Hungary & Department of Pathology, Albert Szent-Györgyi Medical Center, University of Szeged, Szeged, Hungary., Schnitt S; Brigham and Women's Hospital, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA., Larsimont D; Department of Pathology, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, Belgium., Kulka J; Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, Budapest, Pest, Hungary., Fernandez PL; Hospital German Trias i Pujol, Universidad Autonoma de Barcelona, Barcelona, Spain., Rodríguez-Martínez P; Hospital German Trias i Pujol, Universidad Autonoma de Barcelona, Barcelona, Spain., Olivar AA; University Hospital Doctor Josep Trueta, Girona, Spain., Melendez C; University Hospital Doctor Josep Trueta, Girona, Spain., Van Bockstal M; Department of Pathology, Cliniques universitaires Saint-Luc Bruxelles, Woluwé-Saint-Lambert, Brussels, Belgium., Kovacs A; Department of Clinical Pathology, Sahlgrenska University Hospital, Gothenburg, Sweden., Varga Z; Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland., Wesseling J; Divisions of Molecular Pathology and Diagnostic Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands., Bhargava R; Department of Pathology, UPMC Magee-Womens Hospital, Pittsburgh, PA, USA., Boström P; Department of Pathology, Turku University Hospital and University of Turku, Turku, Finland., Franchet C; Institut Claudius Regaud, Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France., Zambuko B; Department of Pathology, Sir Ketumile Masire Teaching Hospital, University of Botswana, Gaborone, Botswana., Matute G; Clínica Universitaria Bolivariana, Universidad Pontificia Bolivariana, Medellín, Colombia., Mueller S; Institute of Pathology, Hannover Medical School, Hannover, Germany., Berghian A; Department of Biopathology, Centre Henri Becquerel, Rouen, France., Rakha E; Department of Histopathology, Nottingham University Hospital NHS Trust, City Hospital Campus Hucknall Road, Nottingham, UK., van Diest PJ; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands., Oesterreich S; Women's Cancer Research Center, UPMC Hillman Cancer Center, Magee-Womens Research Institute, Pittsburgh, PA, USA., Derksen PWB; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands., Floris G; Department of Pathology, University Hospitals Leuven, UZ Leuven, Leuven, Belgium. giuseppe.floris@uzleuven.be., Desmedt C; Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium. christine.desmedt@kuleuven.be.
Jazyk: angličtina
Zdroj: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc [Mod Pathol] 2022 Dec; Vol. 35 (12), pp. 1812-1820. Date of Electronic Publication: 2022 Aug 03.
DOI: 10.1038/s41379-022-01135-2
Abstrakt: Invasive lobular carcinoma (ILC) represents the second most common subtype of breast cancer (BC), accounting for up to 15% of all invasive BC. Loss of cell adhesion due to functional inactivation of E-cadherin is the hallmark of ILC. Although the current world health organization (WHO) classification for diagnosing ILC requires the recognition of the dispersed or linear non-cohesive growth pattern, it is not mandatory to demonstrate E-cadherin loss by immunohistochemistry (IHC). Recent results of central pathology review of two large randomized clinical trials have demonstrated relative overdiagnosis of ILC, as only ~60% of the locally diagnosed ILCs were confirmed by central pathology. To understand the possible underlying reasons of this discrepancy, we undertook a worldwide survey on the current practice of diagnosing BC as ILC. A survey was drafted by a panel of pathologists and researchers from the European lobular breast cancer consortium (ELBCC) using the online tool SurveyMonkey®. Various parameters such as indications for IHC staining, IHC clones, and IHC staining procedures were questioned. Finally, systematic reporting of non-classical ILC variants were also interrogated. This survey was sent out to pathologists worldwide and circulated from December 14, 2020 until July, 1 2021. The results demonstrate that approximately half of the institutions use E-cadherin expression loss by IHC as an ancillary test to diagnose ILC and that there is a great variability in immunostaining protocols. This might cause different staining results and discordant interpretations. As ILC-specific therapeutic and diagnostic avenues are currently explored in the context of clinical trials, it is of importance to improve standardization of histopathologic diagnosis of ILC diagnosis.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz: